NCT03260491: U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
- State
- Under way
- Phase
- Phase 1
- People
- 312 taking part
- Started
- 30 Oct 2017
- Primary completion
- 1 Dec 2025
- Arms
- Dose Escalation: Cohort 1, 3.2 mg/kg, Dose Escalation: Cohort 2, 4.8 mg/kg, Dose Escalation: Cohort 3, 5.6 mg/kg, Dose Escalation: Cohort 4, 6.4 mg/kg, Dose Expansion: Cohort 1, EGFR mutant, Dose Expansion: Cohort 2, EGFR wild-type, Dose Expansion: Cohort 3a, EGFR mutant, Dose Expansion: Cohort 3b, EGFR mutant, Dose Expansion: Cohort 4, EGFR mutant, Dose Expansion: Cohort 5, KRAS-G12C mutant NSCLC
- Results
- None posted
- 24 Aug 2017: Trial registered
- 30 Oct 2017: Trial started